Company’s Innovative Breast Cancer Detection Product is Compatible with Hologic, GE and Siemens Digital Breast Tomosynthesis Systems Significantly Expanding iCAD’s Global Market Opportunity VIENNA, ...
NASHUA, N.H. and LOS ANGELES, April 6, 2017 /PRNewswire/ -- (Booth #300) – iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for ...
NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence ...
<0> For iCADKevin Burns, 937-431-7967orFor iCAD investor relationsLHAAnne Marie Fields, 212-838-3777 x6604orFor iCAD media inquiriesSchwartz MSLHelen Shik, 781-684-0770 </0> .(NASDAQ: ICAD),an ...
The FDA approved iCAD’s artificial intelligence-based solution that streamlines the interpretation of breast tomosynthesis, or 3D mammograms, slashing the amount of time it takes a radiologist to read ...
Latest digital breast 3D tomosynthesis solution builds on deep learning technology to improve radiologist workflow and significantly reduce reading time "Following the recent approval from the FDA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback